Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: The OLIVIA multinational randomised phase II trial

Annals of Oncology

Volumn 26, Issue 4, 2015, Pages 702-708

  Gruenberger, Thomas ^a   Bridgewater, J ^b   Chau, I ^c   Garcia Alfonso P ^d   Rivoire, M ^e   Mudan, S ^c   Lasserre, S ^f   Hermann, F ^f   Waterkamp, D ^g   Adam, R ^h  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e UNIVERSITÉ LYON 1   (France)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g GENENTECH INC   (United States)

^h INSERM   (France)

Author keywords

Bevacizumab; Chemotherapy; Colorectal cancer; Liver metastases; Secondary resection

Indexed keywords

BEVACIZUMAB; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ARTICLE; AUSTRIA; CANCER PATIENT; CAUSE OF DEATH; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FRANCE; HEMIHEPATECTOMY; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; INTENTION TO TREAT ANALYSIS; INTESTINE PERFORATION; KIDNEY FAILURE; LIVER FAILURE; LIVER METASTASIS; LIVER WEIGHT; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PORTAL VEIN EMBOLISATION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RESIDUAL VOLUME; SAFETY; SECTORECTOMY; SEGMENTECTOMY; SEPSIS; SINGLE DRUG DOSE; SPAIN; SURGICAL TECHNIQUE; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; ADULT; AGED; ANALOGS AND DERIVATIVES; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; FOLLOW UP; LIVER NEOPLASMS; LIVER RESECTION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL RATE;

EID: 84926460438     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu580     Document Type: Article

References (24)

1. LiverMetSurvey: an international registry of liver metastases of colorectal cancer. www.livermetsurvey.org (updated June 2012) (22 July 2014, date last accessed).
2. Ferrarotto R, Pathak P, Maru D et al. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 2011; 10: 178-182.
3. Adam R, Haller DG, Poston G et al. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol 2010; 21: 1579-1584.
4. Nordlinger B, Van Cutsem E, Rougier P et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43: 2037-2045.
5. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657.
6. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-2516.
7. National Cancer Comprehensive Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines©). Colon cancer, 2014, version 2. http://www.nccn. org/professionals/physician_gls/pdf/colon.pdf (26 November 2013, date last accessed).
8. Adam R, De Gramont A, Figueras J et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012; 17: 1225-1239.
9. Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47.
10. Wong R, Cunningham D, Barbachano Y et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011; 22: 2042-2048.
11. Loupakis F, Cremolini C, Masi G et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609-1618.
12. Masi G, Loupakis F, Salvatore L et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 845-852.
13. Ychou M, Rivoire M, Thezenas S et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol 2013; 20: 4289-4297.
14. Folprecht G, Gruenberger T, Bechstein W et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 2014; 25: 1018-1025.
15. Ye LC, Liu TS, Ren L et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liverlimited metastases. J Clin Oncol 2013; 31: 1931-1938.
16. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
17. Schmoll HJ, Cunningham D, Sobrero A et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 2012; 30: 3588-3595.
18. Saltz L, Badarinath S, Dakhil S et al. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin Colorectal Cancer 2012; 11: 101-111.
19. Cauchy F, Aussilhou B, Dokmak S et al. Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg 2012; 256: 746-752.
20. Reddy SK, Morse MA, Hurwitz HI et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206: 96-106.
21. Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835.
22. Okines A, Puerto OD, Cunningham D et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033-1038.
23. Tamandl D, Gruenberger B, Klinger M et al. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a casecontrolled study. Ann Surg 2010; 252: 124-130.
24. Voest EE, Snoeren N, Schouten SB et al. A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer. J Clin Oncol 2011; 29(suppl): abstract 3565.